Companies Viking Therapeutics, Inc.
Viking Therapeutics (VKTX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Viking Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers94th pct.Of 18 peer CEOs
CEO pay, last three years
- $12,628,061FY2023
- $14,298,554FY2024
- $21,269,833FY2025
CEO total pay was $21,269,833 in fiscal 2025, up from $14,298,554 in fiscal 2024.
FY2025: salary $672,000 · bonus $0 · stock awards $17,756,817 · option awards $2,468,016
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Viking Therapeutics, Inc. in fiscal 2025?
As disclosed, Brian Lian (Chief Executive Officer) was the highest-paid executive at Viking Therapeutics, Inc. in fiscal 2025, with total compensation of $21,269,833.
How does Viking Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Brian Lian's total compensation ranked at the 94th percentile of Viking Therapeutics, Inc.'s disclosed peer group.
What is Viking Therapeutics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Viking Therapeutics, Inc.'s CEO-to-median employee pay ratio was 49:1.
How did shareholders vote on Viking Therapeutics, Inc.'s executive compensation?
As disclosed, 70.19% of shareholders supported Viking Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Viking Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Viking Therapeutics, Inc. reported total board compensation of $442,555 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Brian Lian | $672,000 | $0 | $17,756,817 | $2,468,016 | $373,000 | $0 | $0 | $21,269,833 |
| Chief Executive Officer | ||||||||
| Marianne Mancini | 540,000 | 0 | 3,225,328 | 1,172,544 | 225,000 | 0 | 0 | 5,162,872 |
| Chief Operating Officer | ||||||||
| Greg Zante | 521,000 | 0 | 3,225,328 | 1,172,544 | 217,000 | 0 | 0 | 5,135,872 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Brian Lian | $21,269,833 | $14,298,554 | $12,628,061 | ↑ +6,971,279 |
| Marianne Mancini | 5,162,872 | 4,703,394 | 3,510,957 | ↑ +459,478 |
| Greg Zante | 5,135,872 | 4,681,394 | 3,495,957 | ↑ +454,478 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's executive compensation consists of base salary, annual cash incentives, and equity awards. Base salary provides competitive pay to attract and retain executives, while annual cash incentives and equity awards are designed to align executive compensation with the Company's performance and long-term stockholder value.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Lian | OPTION | 2025-01-03 | — | — | 78,300 | — | $2,468,016 |
| Brian Lian | PSU | 2025-01-03 | — | 145,000 | — | 193,333 | 8,292,052 |
| Greg Zante | RSU | 2025-01-03 | — | — | 44,533 | — | 1,910,020 |
| Marianne Mancini | RSU | 2025-01-03 | — | — | 44,533 | — | 1,910,020 |
| Marianne Mancini | PSU | 2025-01-03 | — | 23,000 | — | 30,667 | 1,315,307 |
| Brian Lian | RSU | 2025-01-03 | — | — | 92,800 | — | 3,980,192 |
| Greg Zante | PSU | 2025-01-03 | — | 23,000 | — | 30,667 | 1,315,307 |
| Greg Zante | OPTION | 2025-01-03 | — | — | 37,200 | — | 1,172,544 |
| Marianne Mancini | OPTION | 2025-01-03 | — | — | 37,200 | — | 1,172,544 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian Lian | $3,980,192 | $8,292,052 | $2,468,016 | 56.3% |
| Greg Zante | 1,910,020 | 1,315,307 | 1,172,544 | 29.9% |
| Marianne Mancini | 1,910,020 | 1,315,307 | 1,172,544 | 29.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Marianne Mancini | PSU | 11,883 | — | $418,044 |
| Greg Zante | PSU | 11,883 | — | 418,044 |
| Marianne Mancini | PSU | 28,333 | — | 996,755 |
| Greg Zante | PSU | 28,333 | — | 996,755 |
| Greg Zante | Option | 30,000 | 4.88 | — |
| Marianne Mancini | PSU | 30,223 | — | 1,063,245 |
| Greg Zante | PSU | 30,223 | — | 1,063,245 |
| Marianne Mancini | Option | 37,200 | 42.89 | — |
| Greg Zante | Option | 37,200 | 42.89 | — |
| Marianne Mancini | PSU | 43,333 | — | 1,524,455 |
| Greg Zante | PSU | 43,333 | — | 1,524,455 |
| Marianne Mancini | Option | 43,500 | 4.88 | — |
| Marianne Mancini | PSU | 44,533 | — | 1,566,671 |
| Greg Zante | PSU | 44,533 | — | 1,566,671 |
| Marianne Mancini | PSU | 46,667 | — | 1,641,745 |
| Greg Zante | PSU | 46,667 | — | 1,641,745 |
| Marianne Mancini | PSU | 63,333 | — | 2,228,055 |
| Greg Zante | PSU | 63,333 | — | 2,228,055 |
| Brian Lian | PSU | 74,916 | — | 2,635,545 |
| Brian Lian | Option | 78,300 | 42.89 | — |
| Brian Lian | PSU | 88,889 | — | 3,127,115 |
| Brian Lian | PSU | 92,800 | — | 3,264,704 |
| Brian Lian | Option | 97,500 | 4.88 | — |
| Marianne Mancini | Option | 102,000 | 8.52 | — |
| Greg Zante | Option | 102,000 | 8.52 | — |
| Brian Lian | PSU | 106,667 | — | 3,752,545 |
| Marianne Mancini | Option | 116,250 | 17.4 | — |
| Greg Zante | Option | 116,250 | 17.4 | — |
| Brian Lian | RSU | 120,843 | — | 4,251,257 |
| Brian Lian | PSU | 150,000 | — | 5,277,000 |
| Brian Lian | Option | 270,000 | 17.4 | — |
| Brian Lian | Option | 300,000 | 8.52 | — |
| Brian Lian | PSU | 326,667 | — | 11,492,145 |
| Brian Lian | PSU | 443,333 | — | 15,596,455 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| S. Kathryn Rouan, Ph.DIndependent · Nominating and Corporate Governance (Chair) | $60,000 | $0 | $548,308 | — | $64,355 | $672,663 |
| Lawson Macartney, B.V.M.S., Ph.DIndependent · Audit · Compensation · Nominating and Corporate Governance | 107,500 | 0 | 548,308 | — | 8,200 | 664,008 |
| J. Matthew SingletonIndependent · Audit (Chair) · Compensation | 77,500 | 0 | 548,308 | — | 0 | 625,808 |
| Charles A. Rowland JrIndependent · Audit · Compensation (Chair) | 75,000 | 0 | 548,308 | — | 0 | 623,308 |
| Matthew W. FoehrIndependent | 50,000 | 0 | 548,308 | — | 0 | 598,308 |
| Brian Lian, Ph.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $548,308 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $50,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $370,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $72,555 |
| Total cost of the board | $442,555 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Viking Therapeutics as a peer
Companies that benchmark against VKTX
6 companies name VKTX as a compensation peer
- 89bio, Inc.ETNBFY2024
- Akero Therapeutics, Inc.AKROFY2024
- Apogee Therapeutics, Inc.APGEFY2025
- Kymera Therapeutics, Inc.KYMRFY2025
- Protagonist Therapeutics, IncPTGXFY2025
- SOLENO THERAPEUTICS INCSLNOFY2024
Each company listed discloses VKTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VKTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
RNA Avidity Biosciences, Inc.RVMD Revolution Medicines, Inc.ARWR Arrowhead Pharmaceuticals, Inc.BBIO BridgeBio Pharma, Inc.CRNX Crinetics Pharmaceuticals, Inc.CYTK Cytokinetics, IncorporatedDYN Dyne Therapeutics, Inc.KRYS Krystal Biotech Inc.MDGL Madrigal Pharmaceuticals, Inc.PTGX Protagonist Therapeutics Inc.RYTM Rhythm Pharmaceuticals Inc.SMMT Summit Therapeutics Inc.UTHR United Therapeutics CorporationPCVX Vaxcyte, Inc.AKRO Akero Therapeutics, Inc.FOLD Amicus Therapeutics, Inc.ITCI Intra-Cellular Therapies, Inc.SWTX SpringWorks Therapeutics, Inc.
Peer reciprocity
The companies Viking Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Summit Therapeutics Inc. | 2025 | Mahkam Zanganeh | $616,500 | $0 | $245,021,384 | $0 | $246,047,279 |
| 2 | Viking Therapeutics, Inc. | 2025 | Brian Lian | 672,000 | 17,756,817 | 2,468,016 | 373,000 | 21,269,833 |
| 3 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 4 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 5 | Rhythm Pharmaceuticals Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 6 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 7 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 8 | Revolution Medicines, Inc. | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 9 | Vaxcyte, Inc. | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 10 | Avidity Biosciences, Inc. | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 11 | Protagonist Therapeutics Inc. | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 12 | Cytokinetics, Incorporated | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 13 | Crinetics Pharmaceuticals, Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 14 | Akero Therapeutics, Inc. | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 15 | Krystal Biotech Inc. | 2025 | Krish Krishnan | 846,167 | 4,104,825 | 4,675,093 | 0 | 10,442,485 |
| 16 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 17 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 18 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 19 | Dyne Therapeutics, Inc. | 2025 | John Cox | 721,000 | 0 | 937,893 | 410,970 | 2,076,868 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Viking Therapeutics, Inc. | not disclosed | not disclosed | No | Aon |
| Akero Therapeutics, Inc. | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Arrowhead Pharmaceuticals, Inc. | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Avidity Biosciences, Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Crinetics Pharmaceuticals, Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Cytokinetics, Incorporated | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Dyne Therapeutics, Inc. | 95% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Krystal Biotech Inc. | 100% | not disclosed | not disclosed | Compensia, Inc. |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Protagonist Therapeutics Inc. | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Revolution Medicines, Inc. | 146% | Option 70 · RSU 30 | not disclosed | Compensia |
| Rhythm Pharmaceuticals Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Summit Therapeutics Inc. | 105% | Options 100 | not disclosed | not disclosed |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Vaxcyte, Inc. | 105% | not disclosed | not disclosed | Pay Governance |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 30,045,938 | 12,763,135 | 401,396 | 70.19% | Passed |
| 2025 | 2025-05-20 | 29,265,273 | 14,490,719 | 506,834 | 66.88% | Passed |
| 2024 | 2024-05-21 | 63,234,707 | 4,510,461 | 193,862 | 93.34% | Passed |
| 2023 | 2023-06-13 | 53,378,794 | 1,290,698 | 119,550 | 97.64% | Passed |
| 2022 | 2022-05-24 | 25,223,961 | 1,710,747 | 861,284 | 93.65% | Passed |
| 2021 | 2021-05-20 | 25,645,023 | 3,320,173 | 211,978 | 88.54% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-19 | 70.19%a |
| 2025 | 2025-05-20 | 66.88%b |
| 2024 | 2024-05-21 | 93.34%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 49 : 1 |
|---|---|
| CEO total compensation | $21,269,833 |
| Median employee compensation | $438,331 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Hubert C. Chen | Chief Medical Officer | 2026-06-01 | A | 190,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Lian | Director | 2026-07-28 | A | 221,667 | 0 | 0 | Common | Form 4 ↗ |
| Marianne Mancini | Chief Operating Officer | 2026-07-28 | A | 31,667 | 0 | 0 | Common | Form 4 ↗ |
| Greg Zante | Chief Financial Officer | 2026-07-28 | A | 31,667 | 0 | 0 | Common | Form 4 ↗ |
| Marianne Mancini | Chief Operating Officer | 2026-07-29 | D | 18,217 | 33 | 609,636 | Common | Form 4 ↗ |
| Brian Lian | Director | 2026-07-29 | D | 148,517 | 33 | 4,947,888 | Common | Form 4 ↗ |
| Greg Zante | Chief Financial Officer | 2026-07-29 | D | 21,217 | 33 | 710,141 | Common | Form 4 ↗ |
| Dorothy Elizabeth Kelly-Gemmell | Director | 2026-08-01 | A | 40,800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dorothy Elizabeth Kelly-Gemmell | Director | 2026-08-01 | A | 6,333 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (55 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Brian Lian. DEF 14A, filed 2026-04-01. Section “Executive Compensation” · page 26. As printed: 21,269,833. View filing ↗
- Section 01, Marianne Mancini. DEF 14A, filed 2026-04-01. Section “Executive Compensation”. As printed: 5,162,872. View filing ↗
- Section 01, Greg Zante. DEF 14A, filed 2026-04-01. Section “Executive Compensation”. As printed: 5,135,872. View filing ↗
- Section 03, Brian Lian OPTION. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Lian PSU. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Greg Zante RSU. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Marianne Mancini RSU. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Marianne Mancini PSU. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Lian RSU. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Greg Zante PSU. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Greg Zante OPTION. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Marianne Mancini OPTION. DEF 14A, filed 2026-04-01. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-01. Section “CEO Pay Ratio”. As printed: 49 : 1. View filing ↗
- Section 08, S. Kathryn Rouan, Ph.D. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 672,663. View filing ↗
- Section 08, Lawson Macartney, B.V.M.S., Ph.D. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 664,008. View filing ↗
- Section 08, J. Matthew Singleton. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 625,808. View filing ↗
- Section 08, Charles A. Rowland Jr. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 623,308. View filing ↗
- Section 08, Matthew W. Foehr. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 598,308. View filing ↗
- Section 08, Brian Lian, Ph.D. DEF 14A, filed 2026-04-01. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Hubert C. Chen 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Lian 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marianne Mancini 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Greg Zante 2026-07-28. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marianne Mancini 2026-07-29. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Lian 2026-07-29. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Greg Zante 2026-07-29. Form 4, filed 2026-07-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dorothy Elizabeth Kelly-Gemmell 2026-08-01. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dorothy Elizabeth Kelly-Gemmell 2026-08-01. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-26. Item 5.07 · say-on-pay result. As reported: 70.19% (votes for as printed: 30,045,938). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-27. Item 5.07 · say-on-pay result. As reported: 66.88% (votes for as printed: 29,265,273). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-23. Item 5.07 · say-on-pay result. As reported: 93.34% (votes for as printed: 63,234,707). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 370,000 + equity 0 + all other 72,555 = 442,555, summed across the director compensation table rows.
- Summit Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Summit Therapeutics Inc.'s own proxy. As printed: 246,047,279. View filing ↗
- Viking Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Viking Therapeutics, Inc.'s own proxy. As printed: 21,269,833. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
- Rhythm Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- SpringWorks Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. View filing ↗
- BridgeBio Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. View filing ↗
- Revolution Medicines, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. View filing ↗
- Vaxcyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. View filing ↗
- Avidity Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Avidity Biosciences, Inc.'s own proxy. As printed: 14,176,480. View filing ↗
- Protagonist Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics Inc.'s own proxy. As printed: 12,871,506. View filing ↗
- Cytokinetics, Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics, Incorporated's own proxy. As printed: 11,881,456. View filing ↗
- Crinetics Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. View filing ↗
- Akero Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero Therapeutics, Inc.'s own proxy. As printed: 10,465,855. View filing ↗
- Krystal Biotech Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Krystal Biotech Inc.'s own proxy. As printed: 10,442,485. View filing ↗
- Intra-Cellular Therapies, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. View filing ↗
- Arrowhead Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Dyne Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dyne Therapeutics, Inc.'s own proxy. As printed: 2,076,868. View filing ↗
- Section 10a, Protagonist Therapeutics Inc. reciprocity. DEF 14A. Protagonist Therapeutics Inc. names Viking Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Akero Therapeutics, Inc. reciprocity. DEF 14A. Akero Therapeutics, Inc. names Viking Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗